Jefferies Raises Medivation (MDVN) Price Target to $95
Tweet
Share
E-mailGet Alerts MDVN Hot Sheet
Price: $81.44 --0%
Rating Summary:
12 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
12 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Jefferies boosted its price target on Medivation (NASDAQ: MDVN) from $62 to $95 while reiterating their Buy rating following "robust" AFFIRM data on all fronts.
The firm comments, "MDVN released further details from the Ph 3 AFFIRM trial evaluating MDV3100 in castrate-resistant prostate cancer (CRPC) which will be presented at ASCO-GU on Feb 2. While the interim top-line data were release in early Nov, the additional dataset reveals a stellar efficacy/safety profile."
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $55.41 yesterday.
The firm comments, "MDVN released further details from the Ph 3 AFFIRM trial evaluating MDV3100 in castrate-resistant prostate cancer (CRPC) which will be presented at ASCO-GU on Feb 2. While the interim top-line data were release in early Nov, the additional dataset reveals a stellar efficacy/safety profile."
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $55.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cummins (CMI) PT Lowered to $675 at Jefferies
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
- DA Davidson Starts Comfort Systems USA (FIX) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Hot CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
